CD274 and non-small cell lung carcinoma: For example, (Figure 2), in non-small cell lung cancer, secreted PD-L1 splicing isoforms can compete for binding PD-L1 antibodies, resulting in resistance to PD-L1 blockade therapy (Gong et al., 2019).